Chordia Therapeutics Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting ...Middle East

KANAGAWA, Japan, June 7, 2022 /PRNewswire/ -- Chordia Therapeutics Inc. ("Chordia"), a biotech company engaged in the research and development of novel therapies for cancers, today announced that it has presented the interim results from the Phase 1 clinical trial of CTX-712, a selective...

Hence then, the article about chordia therapeutics announces interim results of the phase 1 clinical trial of clk inhibitor ctx 712 at the 2022 asco annual meeting was published today ( Tuesday 07/06/2022 - 09:12 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Chordia Therapeutics Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting )

Also on site :

• Belgium corrects US on ‘peace board’ claim
• Why is South Africa upset about Iran joining BRICS naval drills?
• Numbrix 9 - January 23